Flagship allergy hope, Resigercept positions Yuhan in biologics race

With Phase 1b repeat-dose data now public, Yuhan’s investigational biologic Resigercept (YH35324) is emerging as a flagship pipeline asset in allergic disease. The long-acting anti-IgE candidate showed sustained IgE suppression and a clean safety profile in early trials.

Edited by ad hoc news Flagship & Bestseller Desk. Reviewed before publication on 06/15/2026 at 7:22 PM ET. Details in the imprint.

Repeated-dose Phase 1b data are turning Resigercept (development code YH35324) into one of Yuhan’s most closely watched flagship assets, with the investigational long-acting allergy biologic demonstrating sustained suppression of free IgE and a favorable safety profile compared with placebo and omalizumab in early clinical testing. Yuhan is developing Resigercept as a next-generation anti-IgE therapy for allergic diseases such as chronic spontaneous urticaria and other IgE-mediated conditions, positioning the molecule as a potential crown jewel in its pipeline rather than a conventional small-molecule drug.

What Resigercept is designed to do

Resigercept is described by the company as a long-acting, high-affinity anti-immunoglobulin E (IgE) "IgETrap-Fc" fusion protein new drug candidate, essentially engineered to bind circulating IgE with high potency and keep levels suppressed over an extended period. According to a recent English-language report summarizing Yuhan’s latest clinical update, the molecule acts as a trap for IgE in the bloodstream, potentially offering deeper and more durable control of allergic inflammation than first-generation biologics that simply block the IgE receptor. Seoul Economic Daily reports that Resigercept is a long-acting, high-affinity anti-IgE IgETrap-Fc fusion protein and a key new drug candidate for allergic disease in Yuhan’s pipeline.

In a repeat-dose Phase 1b study presented at the European Academy of Allergy and Clinical Immunology (EAACI) Congress, Resigercept reportedly showed dose-dependent pharmacokinetics and pharmacodynamics: as the dose increased, drug exposure rose and free IgE levels in the blood fell more sharply, with the reduction effect tending to last longer at higher cohorts. Investigators highlighted Cohort 3, composed of patients with high baseline IgE levels, where the median duration with blood free IgE concentrations maintained below 25 ng/mL reached 15 days in the Resigercept arm, versus zero days in both the placebo and omalizumab comparator groups, suggesting more sustained IgE control at least in this small sample. Yuhan has framed this finding as early evidence that its biologic could deliver faster and more durable suppression of free IgE than existing treatments for patients with particularly high IgE burden.

Safety is critical for chronic allergy biologics, which are often used long term, and Resigercept’s initial profile looks encouraging based on the data Yuhan has shared so far. Across repeat dosing in the Phase 1b trial, the company has said there were no drug-related serious adverse events and no trial discontinuations due to adverse events in the Resigercept group, a result that management has used to support the narrative that the molecule can be dosed repeatedly without triggering major tolerability issues in early-stage testing. In comments cited alongside the clinical data, Yuhan’s president and head of R&D Kim Yeol-hong emphasized that repeat-dose administration demonstrated a favorable safety profile while also validating the possibility of faster and more sustained suppression of free IgE versus legacy anti-IgE options, a message clearly aimed at differentiating Resigercept as the company plans later-stage trials.

The mechanism and format also fit a broader trend in allergy and immunology towards engineered fusion proteins and bispecific constructs that can extend half-life or enhance target engagement compared with traditional monoclonal antibodies. By choosing an IgETrap-Fc design, Yuhan is effectively combining a high-affinity IgE-binding domain with an Fc backbone that can improve pharmacokinetics, with the goal of achieving fewer injections and more stable control of symptoms over time. Should this approach translate into Phase 2 and Phase 3 outcomes, Resigercept could be positioned not only as a competitor to omalizumab and other anti-IgE agents but also as a differentiated option for patients who remain symptomatic or require more sustained control despite existing therapies.

Commercially, a successful Resigercept launch would give Yuhan a proprietary biologic in a global allergy therapeutics market populated by both branded biologics and widely used generics, potentially shifting the company’s revenue mix toward higher-margin specialty products. Yuhan has historically been known for its domestic Korean portfolio and partnerships with multinational pharma companies; owning a novel biologic for allergic diseases could open licensing, co-development, or co-commercialization opportunities outside Korea if the data ultimately support regulatory filings in major markets. For payers and physicians, the pitch would likely center on the potential for less frequent dosing, more consistent IgE suppression, and possibly improved outcomes in high-IgE patient subsets where existing drugs show limitations, though all of these claims will need to be backed by larger, controlled studies beyond the current Phase 1b experience.

Within Yuhan’s broader development pipeline, Resigercept stands out as a flagship late-preclinical/early-clinical project in immunology, complementing the company’s oncology and metabolic disease programs and giving it another shot on goal in biologics alongside partnered assets. Yuhan’s official pipeline disclosures in recent years have consistently highlighted YH35324 among core pipeline candidates, underlining its strategic importance for long-term growth if the candidate progresses successfully into pivotal trials and eventual commercialization. In its English-language R&D pipeline overview, Yuhan lists YH35324 (Resigercept) as a key allergy treatment candidate in clinical development, underscoring the molecule’s status as a strategic flagship project. Shares of Yuhan (ISIN KR7000100008) closed on the Korea Exchange in Seoul at KRW 186,000 on 06/14/2026, reflecting investor attention on the company’s biologics and specialty-drug pipeline alongside its established domestic business.

Resigercept flagship profile: key facts

• Product: Resigercept (YH35324)
• Manufacturer: Yuhan Corporation
• Category: Flagship/Bestseller pipeline biologic (allergy)
• Launch date: Not yet launched; in clinical development
• MSRP / Price: Not applicable (investigational product)
• Availability: Available only in clinical trials, primarily in Korea and selected international sites where studies are conducted
• Target audience: Patients with IgE-mediated allergic diseases such as chronic spontaneous urticaria and other conditions where IgE suppression is clinically relevant
• Key differentiator / USP: Long-acting, high-affinity anti-IgE IgETrap-Fc fusion design aimed at sustained and deeper IgE suppression with a favorable early safety profile

This article was a.i.-assisted and editorially reviewed. Product information without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Trading involves risk up to and including the total loss of invested capital.